Search
The Kids Research Institute Australia is pleased to share in $490,000 in State Government funding designed to provide vital support to WA’s innovation sector in the wake of COVID-19.
Australia’s first needle-free, gene-based COVID-19 vaccine study will be spear-headed in WA by The Kids Research Institute Australia thanks to almost $6 million in Coronavirus Research Response funding announced by Health Minister Greg Hunt.
Chile has been hard hit by COVID-19, at times reporting around 6500 new cases a day, with many of these located in the capital Santiago.
Christopher Kefyalew Hannah Blyth Alene Moore MBBS (Hons) DCH FRACP FRCPA PhD BSc, MPH, PhD OAM BSc (Hons) GradDipClinEpi PhD Centre Head, Wesfarmers
Influenza remains an important cause of pediatric morbidity and mortality. Immunisation is critical to prevent hospitalisation and severe disease. The COVID-19 pandemic had far-reaching effects on influenza epidemiology and vaccine use.
Coronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended.
Cancer prevention and care efforts have been challenged by the COVID-19 pandemic and armed conflicts, resulting in a decline in the global Human Development Index (HDI), particularly in low- and middle-income countries. These challenges and subsequent shifts in health care priorities underscore the need to continuously monitor cancer outcome disparities and statistics globally to ensure delivery of equitable and optimal cancer prevention and care in uncertain times.
PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
Vaccination has been a cornerstone of public health, substantially reducing the global burden of infectious diseases, notably evident during the COVID-19 pandemic caused by SARS-CoV-2.
Obesity was a risk factor for severe COVID-19 in children during early outbreaks of ancestral SARS-CoV-2 and the Delta variant. However, the relationship between obesity and COVID-19 severity during the Omicron wave remains unclear.